Description
Mahamox‑CV is a prescription antibiotic medicine used to treat a wide range of bacterial infections in the body. It’s a combination of two medicines — Amoxycillin and Clavulanic acid — that work together to kill bacteria and overcome certain bacterial resistance mechanisms.
📌 Composition
- Amoxycillin: A broad-spectrum penicillin-class antibiotic that kills bacteria by inhibiting their cell wall formation.
- Clavulanic Acid: A beta-lactamase inhibitor that prevents bacteria from destroying amoxycillin, making the antibiotic effective against resistant strains.
The medicine is available in several strengths and forms, such as:
- 250 mg/125 mg tablets
- 500 mg/125 mg tablets
- Dry syrup formulations (e.g., 200 mg/28.5 mg per 5 ml) for children.
❓ What It’s Used For
Mahamox-CV treats bacterial infections in various parts of the body, including:
- Respiratory tract infections (e.g., pneumonia, bronchitis)
- Sinusitis and ear infections
- Urinary tract infections (UTIs)
- Skin and soft tissue infections
- Dental and bone infections
- Other bacterial conditions where susceptible bacteria are involved
⚠️ Important: This antibiotic does not work against viral infections like the common cold or flu.
🧠 How It Works
Amoxycillin kills the bacteria directly, but many bacteria produce enzymes (beta-lactamases) that can inactivate the antibiotic. Clavulanic acid blocks these enzymes, allowing amoxycillin to remain effective.
⚠️ Precautions
- Do not take if you’re allergic to penicillin antibiotics.
- Take as prescribed by a doctor; do not stop early even if symptoms improve.
- Inform your doctor if you have kidney or liver problems.
- Antibiotic courses must be completed fully to help prevent bacterial resistance.
🩺 Common Side Effects
Some people may experience:
- Nausea, vomiting, diarrhea
- Stomach discomfort
- Sometimes mild allergic reactions (rash)
If you need dosage guidance or clarification on whether this medicine is right for a specific condition, I can help with that too!





Reviews
There are no reviews yet.